Tag: axonics

Axonics two year results ARTISAN-SNM study

Axonics announces two-year results from its ARTISAN-SNM study

Two-year results of Axonics’ ARTISAN-sacral neuromodulation (SNM) study demonstrate that patients implanted with the r-SNM system continue to receive clinically meaningful and statistically significant...
Axonics FDA approval Remote Control

Axonics receives FDA approval for 3T full-body MRI scans

Axonics, a company that has developed and is commercialising novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has...
Axonics two year results ARTISAN-SNM study

FDA approval for Axonics’ wireless patient Remote Control with SmartMRI technology

Axonics, a company that has developed implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has announced US Food and...
Axonics two year results ARTISAN-SNM study

Axonics wins FDA approval for its next-generation implantable neurostimulator

Axonics has announced the US Food and Drug Administration (FDA) approval of its next-generation rechargeable implantable neurostimulator for its r-SNM system under a premarket approval...
Axonics two year results ARTISAN-SNM study

FDA approval of Axonics’ enhanced neurostimulator programmer

Axonics announces US Food and Drug Administration (FDA) approval of an enhanced, second-generation programmer for its r-SNM system under a premarket approval (PMA) application...
Axonics two year results ARTISAN-SNM study

Axonics granted six US patents and allowed three additional patents related...

Axonics has announced that the United States Patent and Trademark Office has issued or allowed Axonics nine US utility patents in 2019, along with...
Axonics two year results ARTISAN-SNM study

Axonics provides survey results from Physician Seminar Series showcasing the recently...

  Axonics, a medical technology company that has developed and is commercialising novel implantable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel...
sacral neurmodulation system

Axonics announces US Food & Drug Administration approval for its sacral...

  Axonics, a medical technology company that has developed and is commercialising novel implantable rechargeable sacral neuromodulation (SNM) devices for the treatment of bladder and...
SNM axonics system

Axonics announces first commercial US patient implanted with its sacral neuromodulation...

  Axonics has announced the first US-based implantation of the Axonics r-SNM system subsequent to its clearance by the US Food & Drug Administration (FDA)...
Axonics two year results ARTISAN-SNM study

Axonics provides full one-year results from ARTISAN-SNM pivotal study

  Axonics announced the presentation of detailed one-year results from its ARTISAN rechargeable sacral neuromodulation (r-SMN) pivotal study at a plenary session at the joint...
Axonics FDA approval Remote Control

Axonics announces agreement to supply sacral neuromodulation systems to leading urology...

  Axonics has announced that it has entered into an exclusive agreement to supply the Axonics rechargeable sacral neuromodulation (r-SNM) system to Adult Pediatric Urology...
Axonics FDA approval Remote Control

Axonics announces US FDA approval for its sacral neuromodulation system

Axonics, a medical technology company that has developed and is commercialising a novel implantable rechargeable sacral neuromodulation (SNM) device for the treatment of urinary and...
SNM axonics system

Axonics announces FDA approval for the use of full-body MRI for...

Axonics have announced that the Food & Drug Administration (FDA) approved the use of full-body magnetic resonance imaging (MRI) using 1.5 Tesla MRI scanners...

Welkin Health announces partnership to implement a programme to support commercialisation...

Welkin Health, a privately-held patient relationship management software company has announced that it is partnering with Axonics, a company focused on the design, development,...
SNM axonics system

Axonics granted full-body MR-conditional CE mark for its sacral neuromodulation system

Axonics has announced that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging conditional labelling for the Axonics r-SNM...
SNM axonics system

Axonics announce positive clinical data from its ARTISAN sacral neuromodulation pivotal...

Axonics has disclosed positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the US Food and Drug Administration (FDA)...
SNM axonics system

Axonics secures US$40M financing to commercialise neuromodulation device

Axonics has secured US$40 million to support commercialisation of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the...